In short
Radiprodil is an experimental drug being studied in clinical trials for various neurological conditions, including GRIN-related disorders, infantile spasms, tuberous sclerosis complex, and focal cortical dysplasia. These trials aim to evaluate the safety, effectiveness, and proper dosing of radiprodil in treating seizures and behavioral symptoms associated with these conditions. The drug works by modulating a specific receptor in the brain involved in neurological function.
At a glance
- Drug Name
- Radiprodil
- Mechanism of Action
- Negative allosteric modulator of the NR2B subunit of the NMDA receptor
- Conditions Studied
- GRIN-related disorders, Infantile spasms, Tuberous Sclerosis Complex, Focal Cortical Dysplasia Type II
- Administration
- Oral suspension, twice daily
- Primary Outcomes
- Safety, tolerability, pharmacokinetics, reduction in seizures, improvement in behavioral symptoms
- Trial Phases
- Phase 1B/2A
- Trial Duration
- Varies; initial phase up to 6 months, long-term treatment up to 1 year or more
- Key Assessments
- Adverse events, plasma drug concentrations, seizure frequency, behavioral scales, quality of life measures
What is Radiprodil?
Radiprodil, also known as UCB3491, is a new investigational drug being studied for its potential to treat various neurological disorders. It is currently undergoing clinical trials to evaluate its effectiveness and safety in treating conditions affecting the brain and nervous system.
How Radiprodil Works
Radiprodil is classified as a negative allosteric modulator of the NR2B subunit of the NMDA receptor. To understand this in simpler terms:
- NMDA receptor: This is a protein in brain cells that helps with communication between neurons (brain cells). It plays a crucial role in learning, memory, and brain development.
- NR2B subunit: This is a specific part of the NMDA receptor.
- Negative allosteric modulator: This means Radiprodil can reduce the activity of the NMDA receptor, specifically the part containing the NR2B subunit.
By modulating the activity of these receptors, Radiprodil may help in controlling excessive brain activity that can lead to seizures and other neurological symptoms.
Conditions Treated with Radiprodil
Radiprodil is being investigated for several neurological conditions, including:
- GRIN-related disorders: These are rare genetic conditions affecting brain development and function.
- Infantile Spasms (IS): A rare but serious type of seizure disorder that occurs in young children.
- Tuberous Sclerosis Complex (TSC): A genetic disorder causing non-cancerous tumors to grow in various parts of the body, including the brain.
- Focal Cortical Dysplasia (FCD) Type II: A condition where brain cells don't develop properly, leading to seizures.
Current Clinical Trials
Several clinical trials are currently underway to evaluate Radiprodil:
- HONEYCOMB Study (NCT05818943): This trial is assessing Radiprodil in children with GRIN-related disorders.
- Infantile Spasms Study (NCT02829827): This study is evaluating Radiprodil in children with drug-resistant infantile spasms.
- ASTROSCAPE Study (NCT06392009): This trial is investigating Radiprodil in patients with Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) Type II.
These trials aim to determine the safety, tolerability, and effectiveness of Radiprodil in treating these conditions.
How Radiprodil is Administered
Radiprodil is typically administered as a liquid suspension that can be taken orally or through a feeding tube. The dosage is usually individualized for each patient, meaning the doctor will determine the right amount based on the patient's specific needs and response to the medication.
In clinical trials, the drug is often given twice daily, with the dose gradually increased over time to find the most effective and safe amount for each patient.
Safety and Side Effects
As Radiprodil is still in the investigational stage, its full safety profile is not yet established. The ongoing clinical trials are carefully monitoring for any side effects or adverse reactions.
Some of the aspects being closely monitored include:
- Treatment-Emergent Adverse Events (TEAEs)
- Changes in vital signs (blood pressure, heart rate)
- Changes in ECG readings (heart rhythm)
- Changes in laboratory test results
It's important to note that as an investigational drug, Radiprodil is only available through clinical trials at this time. Patients interested in this treatment should discuss with their healthcare providers about the possibility of participating in a clinical trial.